# The fish that got away: a clinical trial investigating specialized pro-resolving lipid mediators and treatment-resistant depression - URL: https://alisanburak.com/en/wcp-2026-posterler/k5181 - Language: en - Last updated: not specified - Page title: The fish that got away: a clinical trial investigating specialized pro-resolving lipid mediators and treatment-resistant depression | WCP 2026 Summary > An EPA-rich omega-3 preparation administered as an adjunctive treatment for treatment-resistant depression was well tolerated in a small sample; analyses of bi… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/k5181) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. Free Paper (Oral Presentation)PsychopharmacologyRCT # The fish that got away: a clinical trial investigating specialized pro-resolving lipid mediators and treatment-resistant depression The fish that got away: a clinical trial examining specialized pro-resolving lipid mediators and treatment resistant depression Presenter: David Mischoulon Country: United States of America Session: 3162 - FREE COMMUNICATIONS 06: MOOD DISORDERS: MECHANISMS, RISK FACTORS AND NOVEL TREATMENTS Date: Thu, 24.09.2026, 16:45 - 16:55 Room: Hall K11 An EPA-rich omega-3 preparation administered as an adjunctive treatment for treatment-resistant depression was well tolerated in a small sample; analyses of biological and depression-related outcomes are ongoing. The study aimed to investigate the effects of an eicosapentaenoic acid (EPA)-rich preparation on plasma 18-HEPE levels, the relationship between these levels and clinical response, and the preparation's effects on peripheral inflammatory biomarkers; treatment-resistant depression (TRD) remains a challenging condition to manage, and personalized medicine is a growing approach in this field. In a 12-week, placebo-controlled, double-blind, randomized controlled trial, adults diagnosed with treatment-resistant major depression, with a body mass index between 25 and 45 kg/m2 and high-sensitivity C-reactive protein (hs-CRP) levels between 3 and 10 mg/L, received 4 g per day of EPA-rich n-3 as an adjunctive treatment. 18-HEPE and other biomarkers were measured before and after treatment, and depression outcomes were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS). Recruitment was unusually difficult because of additional safety criteria imposed by the funding agency and barriers in the post-pandemic period; a total of 14 participants were randomized, and 11 completed the study. The omega-3 preparation was well tolerated; the most common adverse events were belching (n=2), diarrhea (n=2), and maculopapular rash (n=2); one participant developed uncontrolled hypertension, which was considered unrelated to the intervention, and was withdrawn from the study. Analyses of biological and depression-related findings are ongoing and will be shared during the presentation. The presentation will also discuss the importance of carefully selecting inclusion and exclusion criteria when investigating personalized treatments for depression, as well as more effective recruitment strategies in the post-pandemic period. How to cite this study APA 7: Mischoulon, D., et al. (2026, September 24). The fish that got away: a clinical trial examining specialized pro-resolving lipid mediators and treatment resistant depression [Oral presentation]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. Vancouver: Mischoulon D, et al. The fish that got away: a clinical trial examining specialized pro-resolving lipid mediators and treatment resistant depression [oral presentation]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/k5181 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim